Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were comparable across groups

Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were comparable across groups. file.(38K, docx) jiy743_suppl_Supplementary_materialsClick here for additional data file.(17K, docx) Notes em Acknowledgments. /em ?The authors thank the study participants and their families for their participation to the HPV-048 or HPV-070 study. They also acknowledge the investigators of the HPV-048 (“type”:”clinical-trial”,”attrs”:”text”:”NCT00541970″,”term_id”:”NCT00541970″NCT00541970) and HPV-070 (“type”:”clinical-trial”,”attrs”:”text”:”NCT01381575″,”term_id”:”NCT01381575″NCT01381575) trials as well as their Natamycin (Pimaricin) clinical teams for their support and care of participants. The authors thank the global and regional clinical teams of GSK for their contribution to the study, the R&D group for testing, processing and coordination of laboratory Rabbit polyclonal to AFF3 work, the scientific writers for clinical protocol and clinical report writing as well as the statisticians team for input on statistical analysis. The authors would like to thank Business & Decision Life Sciences platform for editorial assistance and publication coordination, on behalf of GSK. Bruno Baudoux coordinated publication development and editorial support. The authors also thank Valrie Patin (Business & Decision Life Sciences, on behalf of GSK) for providing medical writing support. em Financial support. /em ?This work was supported by GlaxoSmithKline Biologicals SA. em Potential conflicts of interest. /em ?GlaxoSmithKline Biologicals SA supported the HPV-048 and HPV-070 studies and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this article. N. F., J. M., P. M., A. D., S. P., and F. S. are employees of the GSK group of companies; P. V. S. was an employee of the GSK group of companies at the time the study was conducted; and N. F., P. M., S. P., and F. S. hold shares in the GSK group of companies. P. D. declares that the Department of Health Sciences of the University of Genoa had a contract with the GSK group of companies during the conduct of the HPV-070 trial. S. A. M. received grants for unrelated work from GSK, Pfizer, Sanofi, and Merck; consulting fees from Merck and Pfizer; and honoraria and speakers fees from GSK, Merck, Sanofi, and Pfizer for unrelated work. M. D. received a grant from the GSK group of companies through his employer, the CHU of Quebec City, as principal investigator for several GSK clinical trials, including the HPV-048 and HPV-070 studies. S. E. received personal fees from the GSK group of companies, Sanofi Aventis, Merck, and Vifor outside the submitted work and received a grant from the GSK group of companies, Sanofi Aventis, Vifor, Valeas, and DMG outside the submitted work. M. F. received personal fees from the Colchester Research Group (CRG), which is owned by his wife, L. F., in his role as Natamycin (Pimaricin) principal investigator/subinvestigator during the conduct of the study; personal Natamycin (Pimaricin) fees were also paid from CRG outside the submitted work. T. F. S. received personal fees from the GSK group of companies, Pfizer, and Sanofi Pasteur outside the submitted work. All other authors report no potential conflicts. Presented in part: 36th Annual Meeting of the European Society for Paediatric Infectious Diseases, Malm?, Sweden, 29 MayC2 June 2018..